Insurtech’s Health Check: Plum Injects $25M into Preventive Care Revolution

Plum, Bengaluru-based insurtech firm, is embarking on a major new foray into healthcare with a $25 million (Rs 200 crore) funding that will transform employee health all over India.

Strategic Expansion Highlights
- It will be invested over the next 3–4 years, funded entirely from Plum's own internal cash resources and profits

- Plum Health, a new vertical, will offer diagnostics, teleconsultation, and health monitoring through AI, tailored for working professionals
- It is led by Prayat Shah, former co-founder of Wellthy Therapeutics, and has experience in chronic care to deliver.

Technology and Services Deployment
- Plum Health Checkups will be providing in-home testing from 4,000+ sites, including over 200 markers like cardiac and cancer markers

- Reports based on AI will convert complicated diagnostics into chat-like summaries, followed by teleconsultation with Plum's in-house physicians
- The platform combines diagnostics, risk assessments, and follow-ups into smooth digital experience.

Market Vision and Influence
- Plum currently covers more than 6,000 businesses and 600,000 employees, with healthcare predicted to generate 30–40% of revenues in five years

- To date, 5,000+ employees have been screened via health camps, and 71% have chronic risks—indicating the need for proactive care

- It is subscription-based, which allows corporates to tailor annual care packages to employee risk profiles

Prospect Plum's healthcare push is an expression of a broader industry shift toward preventive, analytics-driven care over reactive insurance. With no cost of acquiring a customer and full-stack ownership, the company is well-placed to revolutionize corporate healthcare benefits in India. 

Sources: Moneycontro, YourStory, Economic Times, BW Disrupt, Tech in Asia, SiliconIndia

STORIES YOU MAY LIKE

Capt. B.K. Tyagi Takes Additional Charge As CMD Of SCI Land And Assets Amid Leadership Realignment

MIC Electronics Surges On Railway Orders, BIS Certification And Display Contracts

Lupin Launches Loteprednol Etabonate Eye Drops In US, Targets Seasonal Allergy Market